3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...
Novo Nordisk A/S, Apollo Global Management, BlackRock, Blackstone, Prologis, Welltower, and Ventas are the seven Growth ...
Nutrition supplement maker Glanbia announced plans to sell its underperforming U.S. weight management brand SlimFast on ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...